Page 3 of 3.
• HalioDx has successfully performed critical development phases for Ipsogen® JAK2 510(k) in close collaboration with...
• Immunoscore® Colon is the first standardized immune‐based assay for the classification of cancers
• Immunoscore® has...
• Analyzing both adaptive immunity (CD8+ T cells) and PD-L1 expression status should allow clinicians to improve Immune...
HalioDx sees strong development of its clinical research activity toward precision immunotherapy
HalioDx SAS, an immuno-oncology diagnostic company, today announced the formation of its scientific advisory board...
Immunoscore® has confirmed its potential to become a major component of the colon cancer classification at ASCO 2016. ...
HalioDx SAS, an immuno-oncology diagnostic company, today announced the extension of its agreement with QIAGEN to...
Dr. Jérôme GALON presented today positive results from the Immunoscore® study, an international initiative led by the...
HalioDx, a novel company that designs and develops a new class of immune oncology scoring tests for cancer diagnostics,...
Dr. Jérôme Galon to present results of the Immunoscore® worldwide SITC(1) study during the Gastrointestinal Cancer Oral...
HalioDx SAS, a diagnostic company in immuno-oncology, and NanoString Technologies, Inc, a provider of life science tools...
Marseille - France, February 16, 2016
In the January 2016 issue of OncoImmunology, the study by Berghoff et al....
HalioDx ‘s team is attending this fall the most prestigious scientific meetings in the field of Oncology and...
A management buy-out by the QIAGEN Marseille Executive team
The ambition to become the reference diagnostic company in...